Respirable antisense oligonucleotides as novel therapeutic agents for asthma and other pulmonary diseases

Bibliography

• RIGGS AD, MARTIENSSEN RA, RUSSO VEA: Epigenetic mechanisms of gene regulation: introduction. In: Epige-netic Mechanisms of Gene Regulation. Riggs AD, Martienssen RA, Russo VEA (Eds.), Cold Spring Harbor Laboratory Press (1996) 1–4. This comprehensive volume discusses myriad aspects of epigenetics, the science of gene expression. It is important for the present review for its comprehensive discussion of the breadth of non-genetic changes that occur during the exercise of both normal physiology and in a variety of disease states.
   Google Scholar
• AKHTAR S, AGRAWAL S: In vivo studies with antisense oligonucleotides. Trends Pharmacol Sci. (1997) 18(1):12–18. A description of some of the work being done on the in vivo administration of antisense oligonucleotides.
   Google Scholar
• AGRAWAL S: Antisense oligonucleotides: towards clini- cal trials. Trends Biotechnol (1996) 14(1O):376-387. A description of some of the hurdles, and the crossing of some of them, that have occurred in the field of therapeutic antisense oligonucleotides.
   Google Scholar
• CROOKE ST: Proof of mechanism of antisense drugs. Antisense Nucleic Acid Drug Dev. (1996) 6(2):145–147. A concise primer on what it takes to demonstrate an antisense effect in vitro or in vivo.
   Google Scholar
• HO PT, PARKINSON DR: Antisense oligonucleotides as therapeutics for malignant diseases. Semin. Oncol. (1997) 24(2)187-202. A review of some of the exciting work going on in the antisense for oncology arena.
   Google Scholar
• DEVEREUX S, COTTER FE: Anti-sense and gene therapy approaches to the treatment of lymphomas. Baillieres Haematot (1996) 9 (4) :819-834. A review of DNA-based approaches to the treatment of malignant lymphoma.
   Google Scholar
• WAGNER RW, FLANAGAN WM: Antisense technology and prospects for therapy of viral infections and cancer. Mot. Med. Today (1997) 3(0:31-38. The current progress of two areas of focused attention by antisense researchers, cancer and viral infections, is briefly reviewed.
   Google Scholar
• HALL WA, FLORES EP, LOW WC: Antisense oligonu- cleotides for central nervous system tumors. Neurosur-gery (1996) 38(2) :376-383. Discusses the potential of antisense oligonucleotides for the treat-ment of CNS malignancies, some of which are currently virtually untreatable by classical oncologic drugs.
   Google Scholar
• MORISHITA R, GIBBONS GH, KANEDA Y, OGIHARA T, DZAU VJ: Pharmacokinetics of antisense oligodeoxyri- bonucleotides (cyclin Bland CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene (1994) 149(1) :13-19. Pharmacokinetic data on the delivery of antirestenosis antisense oligonucleotides to the vessel wall in vivo from the laboratory of Victor Dzau.
   Google Scholar
• LIMA WF, BROWN-DRIVER V, FOX M, HANECAK R, BRUICE TW: Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity. J. Biol. Chem. (1997) 272(0:626–638.
   PubMedGoogle Scholar
• SEKI M, HONDA Y: Phosphorothioate antisense oligode-oxynucleotides capable of inhibiting hepatitis C virus gene expression: in vitro translation assay. I Biochem. (1995) 118(6):1199–1204.
   Web of Science ®Google Scholar
• BORDIER B, PERALA-HEAPE M, DEGOLS G et al.: Se- quence-specific inhibition of human immunodefi-ciency virus (HIV) reverse transcription by antisense oligonucleotides: comparative study in cell-free assays and in HIV-infected cells. Proc. Nail. Acad. Sci. USA (1995) 92 (20) 9383–9387. A model study comparing sequence dependent effects in cell-free vs. intact cell systems.
   Google Scholar
• ROBERTSON D: Crohn's trial shows the pros of antis- ?ense. Nature Biotechnol (1997) 15(3):209. Description of recent positive results of an antisense oligonucleotide targeting intracelllular adhesion molecule 1 (ICAM-1) in patients with Crohn's disease.
   Google Scholar
• NEURATH MF, PETTERSSON S, MEYER ZUM BUSCHEN-FELDE KH, STROBER W: Local administration of antis- ense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experi- mental colitis in mice. Nature Med. (1996) 2(9):998–1004. Presents the suprising finding that local administration of antisense oligonucleotides to the colon is efficacious in experimental colitis. Also shows the exciting potential of antisense oligonucleotides targeting the NF-KB transcription factor in inflammatory disease states.
   Google Scholar
• PHILLIPS MI, WIELBO D, GYURKO R: Antisense inhibitionof hypertension: a new strategy for renin-angiotensin candidate genes. Kidney Int. (1994) 46(6) :1554–1556.
   PubMed Web of Science ®Google Scholar
• NYCE JW, METZGER WJ: Antisense DNA for asthma in an animal model. Nature (1997) 385:721-725. The first use of a respirable antisense oligonucleotide effectively and specifically targeting the lung. First identification of the lung as an excellent target for therapeutic antisense intervention in pulmonary disease, possibly because of the presence of surfactant and because inhalation delivers the entire dose of AsON to the target tissue.
   Google Scholar
• SEARS MR: Changing patterns in asthma morbidity andmortality. 1 Invest. Allergol. Gun. Immunol (1995) 5 (2): 66–72.
   Google Scholar
• CALVERLEY PM: Asthma. Postgraduate Med. J. (1996)72(843)12–18.
   Google Scholar
• ANONYMOUS: Asthma-United States, 1982-1992. MMWR- Morbidity & Mortality Weekly Report (1995) 43 (51-52) :952–955.
   PubMedGoogle Scholar
• BARNES PJ, JONSSON B, KLIM JB: The costs of asthma. Eur. Respir. J. (1996) 9(4):636–642. A concise, accurate examination of the costs of asthma both to the patient and society.
   Google Scholar
• LANES SF, BIRMANN B, RAIFORD D, WALKER AM: Inter-national trends in sales of inhaled fenoterol, all inhaled beta-agonists, and asthma mortality, 1970–1992.1 Clin. Epidemiol. (1997) 50(3) :321–328.
   Google Scholar
• GIANGRASSO T: Potential for tolerance, morbidity, and mortality resulting from regular use of beta 2-adrener-gic agonists in asthma. Southern Med. J. (1997) 90(2) 173–179.
   PubMed Web of Science ®Google Scholar
• SUISSA S, HEMMELGARN B, BLAIS L, ERNST, P: Bronchodi-lators and acute cardiac death. Am. J. Respir. Crit. Care Med. (1996) 154(6 Pt. 0:1593.
   Google Scholar
• DJUKANOVIC R, HOMEYARD R, GRATZIOU C et al.: Theeffect of treatment with oral corticosteroids on asthma symptoms and airway inflammation. Am. J. Respir. Crit. Care Med. (1997) 155 (3) :826–832.
   PubMed Web of Science ®Google Scholar
• KAMADA AK, SZEFLER SJ, MARTIN RJ et al.: Issues in theuse of inhaled glucocorticoids. The asthma clinical research network. Am. J. Respir. Crit. Care Med. (1996) 153(6 Pt. 0:1739–1748.
   Google Scholar
• MATSUMOTO H, HASEGAWA T, ISHIHARA K: Concernsabout adverse effects of inhaled corticosteroids [Japa-nese]. Nippon Rinsho - Jpn. Clin. Med. (1996) 54 (1 0 :2998–3003.
   Google Scholar
• IND PW: Anti-leukotriene intervention: is there ade-quate information for clinical use in asthma? Respir. Med. (1996) 90(10575–586.
   Google Scholar
• KRELL RD, GILES RE: Status of leukotriene antagonists and other modulators of lipid mediators. Agents Actions (1993) 41:59–62.
   PubMedGoogle Scholar
• MATHERNE GP, BYFORD AM, GILRAIN JT, DALKIN AC: Changes in myocardial Ai adenosine receptor and mes-sage levels during fetal development and postnatal maturation. Biol. Neonate (1996) 70(4) :199–205.
   PubMedGoogle Scholar
• MEADE CJ, MIREAU J, LEON I, ENSINGER HA: In vivo role of the adenosine A3 receptor: N6-2-(4-amino-phenyfiethyladenosine induces bronchospasm in BDE rats by a neurally mediated mechanism involving cells resembling mast cells. 1 Pharmacol Exp. Ther. (1996) 279(3):1148–1156.
   Google Scholar
• WALKER BAM, JACOBSON MA, KNIGHT DA etal.: Adeno- sine A3 receptor expression and function in eosino- phils. Am. J. Respir. Cell Mot Biol. (1997) 16:531-537. Shows the presence of the adenosine A3 receptor in peripheral eosinophils, where activation of the receptor inhibits eosinophil migration. Demonstrates the desirability to selectively attenuate the A3 receptor in the lungs vs. in the periphery.
   Google Scholar
• JAASKELAINEN I, MONKKONEN J, URTTI A: Oligonu-cleotide-cationic liposome interactions. A physico-chemical study. Biochim. et Biophys. Acta. (1994) 1195(1)115–123.
   Google Scholar
• AGRAWAL S: Dollars and antisense. Sciences (1997) May/June:24-29. A scientific/business perspective of the coming of age of antisense therapeutics. Discusses problems that occurred during the develop-ment of antisense technology, and describes how many of these problems were overcome.
   Google Scholar
• HODGSON D: Antisense companies reach reality. Nature Biotech. (1996) 14:815-816. Briefly reviews some of the cost reductions that have occurred recently in the production of antisense oligonucleotides.
   Google Scholar
• BJORCK T, GUSTAFSSON LE, DAHLEN SE: Isolated bron- chi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leuk-otrienes and histamine. Am. Rev. Respk. Dis. (1992) 145(5):1087–1091. Seminal reference for the development of adenosine Ai-selective antisense oligonucleotide EPI 2010 as an anti-asthma drug.
   Google Scholar
• CHURCH MK, HOLGATE ST: Adenosine in asthmatic lung. Prog. Olin. Biol. Res. (1988) 263:159-66. Seminal reference for the development of adenosine Ai-selective antisense oligonucleotide EPI 2010 as an anti-asthma drug.
   Google Scholar
• BRANCH AD: A hitchhiker's guide to antisense and nonantisense biochemical pathways. Hepatology (1996) 24(6):1517–1529.
   PubMed Web of Science ®Google Scholar
• COULSON JM, POYNER DR, CHANTRY A, IRWIN WJ, AKHTAR S: A nonantisense sequence-selective effect of a phosphorothioate oligodeoxynucleotide directed against the epidermal growth factor receptor in A431 cells. Mol Pharmacol (1996) 50(2):314–325.
   PubMed Web of Science ®Google Scholar
• COLLIS MG, HOURANI SMO: Adenosine receptor sub-types. Trends Pharmacol Sci. Rev. (1993) 14:360–366.
   PubMed Web of Science ®Google Scholar